Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 3, 2006

View Archived Issues

APD-791 antithrombosis agent advanced into preclinical development

NDA filing completed for Genasense plus chemotherapy for CLL

Adolor files IND to begin phase I with ADL-5859

Amylin acquires Ohio facility to manufacture exenatide LAR

GenVec sells myoblast cell therapy program to Mytogen

Aphios licenses vitamin D analogue from Boston University for prostate cancer

LS-104's therapeutic potential for Flt3-ITD positive leukemia

ABI-0043: ActivBiotics' lead preclinical compound against Gram-positive bacterial infections

New agents for endocrine-related disorders disclosed in recent patent literature

AN-0128: Potential antibacterial for a variety of dermatological infections

Novel chemokine CCR2B antagonists from AstraZeneca

Bactericidal profile of new carbacephems emerging from Blanca Pharmaceuticals

ETI-211 clears, protects against Staphylococcus aureus infection

Activity of CG-400549 against Staphylococcus aureus tested in vitro, in vivo

Cephalon completes acquisition of Zeneus

Promising antifungal activity seen with RBx-9050

DNAPrint Genomics acquires Ellipsis Biotherapeutics

Glenmark acquires Bouwer Bartlett

MicroIslet raises funds through sale of common stock

Pharming files for GRAS notification for human lactoferrin

Pharming completes rhC1INH dossier for compassionate use filings

Roche grants Tamiflu sublicense to Hetero Drugs

Discovery Laboratories to acquire Laureate Pharma's manufacturing operations

TD-2749 demonstrates prokinetic effect in healthy volunteers; TD-5108 begins human trials

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for April 27, 2026.
Detecting the invisible: minimal residual disease at AACR 2026
BioWorld Science
Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....
A free gene therapy? Regeneron’s Otarmeni approved for hearing loss
BioWorld
Children and adults with a type of congenital hearing loss now have a free treatment option, with the U.S. FDA’s accelerated approval of Regeneron Pharmaceuticals...
News in brief
BioWorld Asia
BioWorld Asia briefs for April 28, 2026
Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists
BioWorld Science
Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...